STAT+: The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma
STAT
JANUARY 8, 2024
Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development. The deal, disclosed as the biopharma field marked the first day of the annual J.P.
Let's personalize your content